Cobalamin E and G deficiency (cblE, cblG)
Log in to starLast updated Nov 15, 2026
A 5-month-old has poor feeding, hypotonia, developmental delay, and nystagmus. Blood counts show a macrocytic anemia. Plasma total homocysteine is markedly raised and plasma methionine is low; urine methylmalonic acid, serum B12, and folate are normal. Newborn screening was reported normal.
Autosomal recessive. Two genes give one clinical picture, functional methionine synthase deficiency:
- cblE: MTRR (5p15.31), methionine synthase reductase. The most common variant, about 25% of alleles, is c.903+469T>C, deep in intron 6, which activates a pseudoexon. c.1361C>T, common in people of Iberian ancestry, gives a milder picture without neurologic involvement.
- cblG: MTR (1q43), methionine synthase itself. c.3518C>T (p.Pro1173Leu) accounts for about 40% of alleles.
The two were told apart before either gene was known. In the first patient, methionine synthase in broken-cell extracts worked once reducing agents were added; in the next two it did not. Complementation analysis then put the first patient in a separate group, cblE, from the other two, cblG.
Not to be confused with the common MTHFR c.677C>T variant (MTHFR variants), which does not cause homocystinuria.
Methionine synthase remethylates homocysteine to methionine. It carries a methyl group from 5-methyltetrahydrofolate onto its bound cobalamin, forming methylcobalamin, and passes it to homocysteine. Each turn regenerates cob(I)alamin, which now and then oxidizes and leaves the enzyme inactive; methionine synthase reductase restores it by reductive methylation, using S-adenosylmethionine as the methyl donor. Lose either protein and the reaction stops. The mitochondrial branch of cobalamin metabolism is untouched, so adenosylcobalamin is still made and methylmalonic acid stays normal.
Three consequences explain the disease:
- Homocysteine accumulates, usually above 50 and mostly above 100 µmol/L before treatment.
- Methionine falls, and with it S-adenosylmethionine, the methyl donor for DNA methylation, creatine synthesis, and myelin. Low methionine is what separates a remethylation defect from homocystinuria due to CBS deficiency, where methionine is high.
- Folate is trapped. Methionine synthase is the only enzyme that removes the methyl group from 5-methyltetrahydrofolate. When it fails, folate accumulates in that form and nucleotide synthesis is disrupted, which injures fast-dividing tissue such as bone marrow and gives megaloblastic anemia. In MTHFR deficiency 5-methyltetrahydrofolate is never made, nothing is trapped, and megaloblastic anemia does not occur.
Part of cobalamin transport and processing. See also methionine and homocysteine metabolism.
Remethylation of homocysteine, the cytosolic branch of cobalamin metabolism.
processed cobalamin → methylcobalamin on methionine synthase → methionine synthase (MTR, cblG) or its reductase (MTRR, cblE) (the block) → homocysteine + 5-methyltetrahydrofolate → methionine + tetrahydrofolate
- Accumulates: total homocysteine in plasma, with homocystine in urine; folate trapped as 5-methyltetrahydrofolate.
- Missing: methionine and S-adenosylmethionine. Methylmalonic acid is normal.
- Workbook: 4.H. Homocystinuria
cblE and cblG are clinically indistinguishable. Most present in infancy, cblG typically in the first year and cblE in the first two, though onset ranges into adulthood.
- Megaloblastic anemia in most, occasionally as the only finding
- Hypotonia, developmental delay, poor feeding, and growth failure
- Seizures and impaired consciousness in about a third
- Visual impairment in about a quarter: nystagmus, strabismus, retinopathy, optic atrophy
- Microcephaly, brain atrophy, and white matter changes
- Later onset: subacute combined degeneration of the spinal cord, psychiatric illness, leukoencephalopathy; one adult with cblG was first diagnosed with multiple sclerosis
- Rare: atypical hemolytic uremic syndrome or glomerulopathy, thromboembolism
- Plasma total homocysteine first, the hallmark of every remethylation disorder; centrifuge the sample within an hour. Free homocystine on routine amino acid analysis can miss a high total homocysteine
- Before treatment, also measure methylmalonic acid, plasma methionine, serum B12, and folate. The cblE/cblG pattern: high total homocysteine, low methionine, normal methylmalonic acid, normal B12 and folate
- Newborn screening usually misses it. There is no rise in C3, so the methylmalonic acid screen does not flag it; a low methionine (or methionine to phenylalanine ratio) followed by second-tier total homocysteine can, and has found cblE and cblG in some US programs
- Confirm with biallelic MTRR or MTR variants. Methionine synthase and methionine synthase reductase can be assayed directly in fibroblasts; incorporation of labeled methyltetrahydrofolate is low while propionate incorporation is normal, the cellular signature of an isolated remethylation defect
| cblE, cblG | Severe MTHFR deficiency | CBS deficiency (homocystinuria) | Cobalamin C deficiency | |
|---|---|---|---|---|
| Total homocysteine | High | High | High | High |
| Methionine | Low | Low or normal | High or high normal | Low or normal |
| Methylmalonic acid | Normal | Normal | Normal | High |
| Megaloblastic anemia | Yes | No | No | Sometimes |
| Core treatment | Hydroxocobalamin, with betaine | Betaine | Pyridoxine (B6) trial; low-methionine diet and betaine if unresponsive | Hydroxocobalamin, with betaine |
Nutritional B12 or folate deficiency raises homocysteine more mildly, with low serum B12 or folate.
Per the remethylation disorder guidelines (guidelines for the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency, 2017, and the first revision of the guidelines for remethylation disorders, 2026) and GeneReviews:
- Parenteral hydroxocobalamin, started without delay once a remethylation disorder is suspected. The usual start is 1 mg intramuscularly daily, then titrated to metabolic response; frequency ranges from daily to weekly. Most patients with cblE and cblG treated this way appeared to benefit. The 2026 revision adds emerging evidence that early high doses (more than 0.35 mg/kg/day) may improve neurocognitive outcome and eye disease in severe cobalamin-related defects
- Betaine by mouth, up to 250 mg/kg/day in children, in divided doses. It remethylates homocysteine through betaine homocysteine methyltransferase, bypassing methionine synthase. Titrate to total homocysteine and methionine; very high methionine on betaine has caused cerebral edema
- Folic or folinic acid is often added; benefit has been neither shown nor excluded. Folinic acid crosses the blood-brain barrier more readily
- Keep methionine normal, with supplements if needed. Do not restrict protein and do not use methionine-free medical foods, which lower methionine further
- Avoid nitrous oxide, which inactivates methionine synthase; a death has been reported in MTHFR deficiency after nitrous oxide anesthesia. Propofol has been used safely for short procedures
- Pyridoxine does not help unless the patient is B6-deficient
- Follow-up: total homocysteine, methionine, and blood counts; development and neurologic examination; eye examinations, since eye disease often does not respond to treatment while the anemia and neurocognitive features often do
- Recurrence risk 25% for each pregnancy of carrier parents
Empty methionine, Giant red cells: cblE and cblG pair low methionine (unlike CBS deficiency) with megaloblastic anemia (unlike MTHFR deficiency).